Twelve versus 36 months of adjuvant imatinib (IM) as treatment of operable GIST with a high risk of recurrence: Final results of a randomized trial (SSGXVIII/AIO).
Heikki Joensuu, Mikael Eriksson, J. Hatrmann, Kirsten Sundby Hall et autres
0 citations
GRO